Analysis of TCGA-OV and GTEx datasets revealed that the long noncoding RNA ZNF213-AS1 is downregulated in ovarian cancer relative to normal tissue. Low ZNF213-AS1 expression was associated with poorer overall survival in the cohorts analyzed. Transcriptomic correlations linked low ZNF213-AS1 to gene signatures of hypoxia, epithelial-mesenchymal transition (EMT), NF-κB signaling, and IL6/JAK/STAT3 signaling, suggesting ZNF213-AS1 expression aligns inversely with proinvasive and proinflammatory programs in ovarian tumors.
Within ovarian cancer cells, ZNF213-AS1 was reported as relatively abundant and preferentially enriched in the chromatin-associated fraction. This subcellular distribution indicates a likely nuclear or chromatin-related mode of action, consistent with regulatory roles in transcriptional or chromatin-associated complexes rather than purely cytoplasmic microRNA sponging or translation control.
ZNF213-AS1 expression was reduced when ovarian cancer cells were exposed to hypoxic conditions. Notably, the study tested canonical hypoxia regulation and found that repression of ZNF213-AS1 by hypoxia was not rescued by HIF1α knockout. Mutation of a predicted hypoxia response element (HRE) also failed to restore expression under hypoxia. These observations indicate that hypoxic downregulation of ZNF213-AS1 occurs through a noncanonical, HIF1α-independent mechanism, although the exact upstream mediators were not defined in the source.
Functional manipulation of ZNF213-AS1 altered key malignant phenotypes in ovarian cancer models. Overexpression of ZNF213-AS1 suppressed hypoxia-driven increases in colony formation and invasive behavior, and it reduced resistance to the platinum drug cisplatin. By contrast, knockdown of ZNF213-AS1 enhanced colony formation, invasion, and cisplatin resistance. These bidirectional phenotypic results support a tumor-suppressive role for ZNF213-AS1 in limiting hypoxia-associated aggressive features and chemotherapy tolerance.
Mechanistically, ZNF213-AS1 expression inhibited NF-κB reporter activity and led to decreased expression of genes associated with NF-κB, STAT3 activation, and EMT. The coordinated reduction in NF-κB/STAT3/EMT-related transcripts suggests that ZNF213-AS1 restrains a proinflammatory signaling axis that drives EMT and potentially contributes to therapy resistance in ovarian cancer.
Biochemical assays provided evidence of physical association between ZNF213-AS1 and NF-κB complexes containing RELA/p65. Both RNA pull-down and RNA immunoprecipitation (RIP) detected interactions between the lncRNA and p65-containing complexes, supporting a direct or scaffolded mechanism through which ZNF213-AS1 modulates NF-κB activity at the level of complex formation or chromatin recruitment.
To test functional dependence on p65, the investigators re-expressed p65 in contexts of high ZNF213-AS1. p65 re-expression partially reversed ZNF213-AS1–mediated inhibition of STAT3 activation, EMT marker changes, and suppression of xenograft tumor growth. These partial rescues indicate that the inhibitory impact of ZNF213-AS1 on EMT and tumor progression is at least in part mediated through suppression of p65-driven NF-κB activity and downstream STAT3 signaling.
The study defines a hypoxia-repressed lncRNA, ZNF213-AS1, that limits NF-κB/STAT3-driven EMT and platinum-resistant ovarian cancer progression through interaction with RELA/p65. Key findings include dataset-based identification of reduced expression in tumors with prognostic associations, chromatin enrichment, HIF1α-independent repression by hypoxia, functional suppression of invasion and cisplatin resistance, and molecular binding to p65 with functional dependence shown by partial rescue on p65 re-expression.
While the reported work supports a tumor-suppressive axis (ZNF213-AS1 → inhibition of p65 → reduced STAT3/EMT and cisplatin resistance), the source did not report all mechanistic intermediates linking hypoxia to ZNF213-AS1 repression, nor did it provide clinical trial or therapeutic intervention data. The findings suggest ZNF213-AS1 and its interaction with p65/NF-κB could be of interest for future translational studies aiming to counteract hypoxia-driven EMT and platinum resistance in ovarian cancer.